Market Access Multiple myeloma drug Blenrep backed for wider NHS use PharmaphorumThe revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.Market AccessOncologyRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely. Market AccessOncologyRead full story Post navigation Previous: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutionsNext: Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA Related Stories Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026 Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026